Dechra Buys Gallant Pet to Enter Animal Regenerative Medicine
Dechra has acquired U.S. biotech Gallant Pet, adding off-the-shelf mesenchymal stromal cell therapies for pets, with a first product possibly arriving as early as 2027.
Topic
Topic
Dechra has acquired U.S. biotech Gallant Pet, adding off-the-shelf mesenchymal stromal cell therapies for pets, with a first product possibly arriving as early as 2027.